Benign Prostatic Hyperplasia (BPH) Market - Forecast(2019 - 2024)

Report Code: HCR 1258 Report Format: PDF + Excel (Delivery in 48 Hrs)

Benign Prostatic Hyperplasia (BPH) refers to a physical condition in men, which leads to the proliferation of prostatic stromal cells in a non-cancerous way that results in an enlarged prostate gland. Benign prostatic hyperplasia (BPH) is also referred as benign prostatic hypertrophy or benign prostatic obstruction. Owing to the factors such as lack of physical exercise, erectile dysfunction, medical conditions such as obesity, heart and circulatory disease and type2 diabetes are propelling the growth of the market. Moreover, family history of benign prostatic
Hyperplasia and men aged 40 years and above are more prone to the BPH disorder.

The Global Benign Prostatic Hyperplasia (BPH) are classified on the basis of various parameters. On the basis of symptoms the market is classified into Difficulty in Bladder Emptying, Frequent Urination, Straining, Post Urination Dribbling or Weak Stream and Others. On the basis of diagnosis the market is segmented into Prostate-Specific Antigen (PSA) Test, Digital Rectal Examination (DRE) and Others. Based on treatment procedures the market is segregated into Medical Therapies, Surgical Therapies, Minimally Invasive Therapies, Laser Surgical Therapies, Needle Ablation and Others.
GLOBAL BENIGN PROSTATIC HYPERPLASIA (BPH) MARKET VALUE, 2016-2023 ($M)

In terms of Geography, the global Benign Prostatic Hyperplasia (BPH) market is classified into North America, Europe, APAC and Row. North America is expected to be the major player in the Benign Prostatic Hyperplasia (BPH) market followed by Asia Pacific. Asia-Pacific is projected to witness the highest growth during the forecast period having the emerging countries such as China, India and Japan in this region.
Key market players in the global Benign Prostatic Hyperplasia (BPH) market include companies such as Astellas Pharma (Japan), Eli Lilly (U.S.), GlaxoSmithKline (U.K), Sanofi (France) and few others.

1. Benign Prostatic Hyperplasia (BPH) Market - Overview
1.1. Definitions and Scope
2. Benign Prostatic Hyperplasia (BPH) Market - Executive summary
2.1. Market Revenue, Market Size and Key Trends by Company
2.2. Key Trends by type of Application
2.3. Key Trends segmented by Geography
3. Benign Prostatic Hyperplasia (BPH) Market 
3.1. Comparative analysis
3.1.1. Product Benchmarking - Top 10 companies
3.1.2. Top 5 Financials Analysis
3.1.3. Market Value split by Top 10 companies
3.1.4. Patent Analysis - Top 10 companies
3.1.5. Pricing Analysis
4. Benign Prostatic Hyperplasia (BPH) Market – Startup companies Scenario Premium
4.1. Top 10 startup company Analysis by
4.1.1. Investment
4.1.2. Revenue
4.1.3. Market Shares
4.1.4. Market Size and Application Analysis
4.1.5. Venture Capital and Funding Scenario
5. Benign Prostatic Hyperplasia (BPH) Market – Industry Market Entry Scenario Premium
5.1. Regulatory Framework Overview
5.2. New Business and Ease of Doing business index
5.3. Case studies of successful ventures
5.4. Customer Analysis – Top 10 companies
6. Benign Prostatic Hyperplasia (BPH) Market Forces
6.1. Drivers
6.2. Constraints
6.3. Challenges
6.4. Porters five force model
6.4.1. Bargaining power of suppliers
6.4.2. Bargaining powers of customers
6.4.3. Threat of new entrants
6.4.4. Rivalry among existing players
6.4.5. Threat of substitutes 
7. Benign Prostatic Hyperplasia (BPH) Market - Strategic analysis
7.1. Value chain analysis
7.2. Opportunities analysis
7.3. Product life cycle
7.4. Suppliers and distributors Market Share
8. Benign Prostatic Hyperplasia (BPH) Market – By Diagnosis (Market Size -$Million / $Billion)
8.1. Market Size and Market Share Analysis 
8.2. Application Revenue and Trend Research
8.3. Product Segment Analysis
8.3.1. Prostate-Specific Antigen (PSA) Test
8.3.2. Digital Rectal Examination (DRE) 
8.3.3. Others
9. Benign Prostatic Hyperplasia (BPH) Market – By Treatment Procedures (Market Size -$Million / $Billion)
9.1. Medical Therapies
9.1.1. Alpha-Blockers
9.1.1.1. Alfuzosin
9.1.1.2. Doxazosin
9.1.1.3. Tamsulosin
9.1.1.4. Terazosin
9.1.1.5. Others
9.1.2. 5- Alpha-reductase inhibitors (5-ARIs)
9.1.2.1. Dutasteride
9.1.2.2. Finasteride
9.1.3. Combination Therapy
9.1.3.1. Alpha Blocker and 5-Alpha-Reductase Inhibitor
9.1.3.2. Alpha Blocker and Anticholinergics
9.1.4. Anticholinergic Agents
9.2. Surgical Therapies
9.2.1. Open Prostatectomy
9.2.2. Photoselective Vaporization of The Prostate (PVP)
9.2.3. Transurethral Incision of The Prostate (TUIP)
9.2.4. Transurethral Vaporization of The Prostate (TUVP)
9.2.5. Transurethral Resection of the Prostate (TURP)
9.3. Minimally Invasive Therapies
9.3.1. Transurethral needle ablation (TUNA)
9.3.2. Transurethral microwave thermotherapy (TUMT) 
9.4. Laser Surgical Therapies
9.4.1. Holmium Laser Enucleation of the Prostate (HoLEP)
9.4.2. Holmium Laser Ablation of the Prostate (HoLVP)
9.4.3. Holmium laser resection of the prostate (HoLRP)
9.5. Needle Ablation
9.6. Others
10. Benign Prostatic Hyperplasia (BPH) - By Geography (Market Size -$Million / $Billion)
10.1. Benign Prostatic Hyperplasia (BPH) Market - North America Segment Research
10.2. North America Market Research (Million / $Billion)
10.2.1. Segment type Size and Market Size Analysis 
10.2.2. Revenue and Trends
10.2.3. Application Revenue and Trends by type of Application
10.2.4. Company Revenue and Product Analysis
10.2.5. North America Product type and Application Market Size
10.2.5.1. U.S.
10.2.5.2. Canada 
10.2.5.3. Mexico 
10.2.5.4. Rest of North America
10.3. Benign Prostatic Hyperplasia (BPH) - South America Segment Research
10.4. South America Market Research (Market Size -$Million / $Billion)
10.4.1. Segment type Size and Market Size Analysis 
10.4.2. Revenue and Trends
10.4.3. Application Revenue and Trends by type of Application
10.4.4. Company Revenue and Product Analysis
10.4.5. South America Product type and Application Market Size
10.4.5.1. Brazil  
10.4.5.2. Venezuela
10.4.5.3. Argentina
10.4.5.4. Ecuador
10.4.5.5. Peru
10.4.5.6. Colombia 
10.4.5.7. Costa Rica
10.4.5.8. Rest of South America
10.5. Benign Prostatic Hyperplasia (BPH) - Europe Segment Research
10.6. Europe Market Research (Market Size -$Million / $Billion)
10.6.1. Segment type Size and Market Size Analysis 
10.6.2. Revenue and Trends
10.6.3. Application Revenue and Trends by type of Application
10.6.4. Company Revenue and Product Analysis
10.6.5. Europe Segment Product type and Application Market Size
10.6.5.1. U.K  
10.6.5.2. Germany 
10.6.5.3. Italy 
10.6.5.4. France
10.6.5.5. Netherlands
10.6.5.6. Belgium
10.6.5.7. Spain
10.6.5.8. Denmark
10.6.5.9. Rest of Europe
10.7. Benign Prostatic Hyperplasia (BPH) – APAC Segment Research
10.8. APAC Market Research (Market Size -$Million / $Billion)
10.8.1. Segment type Size and Market Size Analysis 
10.8.2. Revenue and Trends
10.8.3. Application Revenue and Trends by type of Application
10.8.4. Company Revenue and Product Analysis
10.8.5. APAC Segment – Product type and Application Market Size
10.8.5.1. China 
10.8.5.2. Australia
10.8.5.3. Japan 
10.8.5.4. South Korea
10.8.5.5. India
10.8.5.6. Taiwan
10.8.5.7. Malaysia
11. Benign Prostatic Hyperplasia (BPH) Market - Entropy
11.1. New product launches
11.2. M&A's, collaborations, JVs and partnerships
12. Benign Prostatic Hyperplasia (BPH) Market – Industry / Segment Competition landscape Premium
12.1. Market Share Analysis
12.1.1. Market Share by Country- Top companies
12.1.2. Market Share by Region- Top 10 companies
12.1.3. Market Share by type of Application – Top 10 companies
12.1.4. Market Share by type of Product / Product category- Top 10 companies
12.1.5. Market Share at global level- Top 10 companies
12.1.6. Best Practises for companies
13. Benign Prostatic Hyperplasia (BPH) Market – Key Company List by Country Premium
14. Benign Prostatic Hyperplasia (BPH) Market Company Analysis
14.1. Market Share, Company Revenue, Products, M&A, Developments
14.2. Astellas Pharma
14.3. Eli Lilly
14.4. GlaxoSmithKline
14.5. Sanofi
14.6. ADC Therapeutics
14.7. Advaxis
14.8. ANI Pharmaceuticals
14.9. Bayer HealthCare
14.10. BHR Pharma
14.11. Bristol-Myers Squibb
14.12. Boehringer Ingelheim
14.13. Novartis
14.14. Teva Pharmaceutical Industries
14.15. Company 14
14.16. Company 15
14.17. Company 16 and More
"*Financials would be provided on a best efforts basis for private companies"
15. Benign Prostatic Hyperplasia (BPH) Market - Appendix
15.1. Abbreviations
15.2. Sources
16. Benign Prostatic Hyperplasia (BPH) Market - Methodology
16.1. Research Methodology
16.1.1. Company Expert Interviews
16.1.2. Industry Databases
16.1.3. Associations
16.1.4. Company News
16.1.5. Company Annual Reports
16.1.6. Application Trends
16.1.7. New Products and Product database
16.1.8. Company Transcripts
16.1.9. R&D Trends
16.1.10. Key Opinion Leaders Interviews
16.1.11. Supply and Demand Trends
List of Table s:

Table 1: Benign Prostatic Hyperplasia (BPH) Market Overview 2019-2024
Table 2: Benign Prostatic Hyperplasia (BPH) Market Leader Analysis 2018-2019 (US$)
Table 3: Benign Prostatic Hyperplasia (BPH) Market Product Analysis 2018-2019 (US$)
Table 4: Benign Prostatic Hyperplasia (BPH) Market End User Analysis 2018-2019 (US$)
Table 5: Benign Prostatic Hyperplasia (BPH) Market Patent Analysis 2013-2018* (US$)
Table 6: Benign Prostatic Hyperplasia (BPH) Market Financial Analysis 2018-2019 (US$)
Table 7: Benign Prostatic Hyperplasia (BPH) Market Driver Analysis 2018-2019 (US$)
Table 8: Benign Prostatic Hyperplasia (BPH) Market Challenges Analysis 2018-2019 (US$)
Table 9: Benign Prostatic Hyperplasia (BPH) Market Constraint Analysis 2018-2019 (US$)
Table 10: Benign Prostatic Hyperplasia (BPH) Market Supplier Bargaining Power Analysis 2018-2019 (US$)
Table 11: Benign Prostatic Hyperplasia (BPH) Market Buyer Bargaining Power Analysis 2018-2019 (US$)
Table 12: Benign Prostatic Hyperplasia (BPH) Market Threat of Substitutes Analysis 2018-2019 (US$)
Table 13: Benign Prostatic Hyperplasia (BPH) Market Threat of New Entrants Analysis 2018-2019 (US$)
Table 14: Benign Prostatic Hyperplasia (BPH) Market Degree of Competition Analysis 2018-2019 (US$)
Table 15: Benign Prostatic Hyperplasia (BPH) Market Value Chain Analysis 2018-2019 (US$)
Table 16: Benign Prostatic Hyperplasia (BPH) Market Pricing Analysis 2019-2024 (US$)
Table 17: Benign Prostatic Hyperplasia (BPH) Market Opportunities Analysis 2019-2024 (US$)
Table 18: Benign Prostatic Hyperplasia (BPH) Market Product Life Cycle Analysis 2019-2024 (US$)
Table 19: Benign Prostatic Hyperplasia (BPH) Market Supplier Analysis 2018-2019 (US$)
Table 20: Benign Prostatic Hyperplasia (BPH) Market Distributor Analysis 2018-2019 (US$)
Table 21: Benign Prostatic Hyperplasia (BPH) Market Trend Analysis 2018-2019 (US$)
Table 22: Benign Prostatic Hyperplasia (BPH) Market Size 2018 (US$)
Table 23: Benign Prostatic Hyperplasia (BPH) Market Forecast Analysis 2019-2024 (US$)
Table 24: Benign Prostatic Hyperplasia (BPH) Market Sales Forecast Analysis 2019-2024 (Units)
Table 25: Benign Prostatic Hyperplasia (BPH) Market, Revenue & Volume, By Diagnosis, 2019-2024 ($)
Table 26: Benign Prostatic Hyperplasia (BPH) Market By Diagnosis, Revenue & Volume, By Prostate-Specific Antigen (PSA) Test, 2019-2024 ($)
Table 27: Benign Prostatic Hyperplasia (BPH) Market By Diagnosis, Revenue & Volume, By Digital Rectal Examination (DRE), 2019-2024 ($)
Table 28: Benign Prostatic Hyperplasia (BPH) Market, Revenue & Volume, By Treatment Procedures, 2019-2024 ($)
Table 29: Benign Prostatic Hyperplasia (BPH) Market By Treatment Procedures, Revenue & Volume, By Medical Therapies, 2019-2024 ($)
Table 30: Benign Prostatic Hyperplasia (BPH) Market By Treatment Procedures, Revenue & Volume, By Surgical Therapies, 2019-2024 ($)
Table 31: Benign Prostatic Hyperplasia (BPH) Market By Treatment Procedures, Revenue & Volume, By Minimally Invasive Therapies, 2019-2024 ($)
Table 32: Benign Prostatic Hyperplasia (BPH) Market By Treatment Procedures, Revenue & Volume, By Laser Surgical Therapies, 2019-2024 ($)
Table 33: Benign Prostatic Hyperplasia (BPH) Market By Treatment Procedures, Revenue & Volume, By Needle Ablation, 2019-2024 ($)
Table 34: North America Benign Prostatic Hyperplasia (BPH) Market, Revenue & Volume, By Diagnosis, 2019-2024 ($)
Table 35: North America Benign Prostatic Hyperplasia (BPH) Market, Revenue & Volume, By Treatment Procedures, 2019-2024 ($)
Table 36: South america Benign Prostatic Hyperplasia (BPH) Market, Revenue & Volume, By Diagnosis, 2019-2024 ($)
Table 37: South america Benign Prostatic Hyperplasia (BPH) Market, Revenue & Volume, By Treatment Procedures, 2019-2024 ($)
Table 38: Europe Benign Prostatic Hyperplasia (BPH) Market, Revenue & Volume, By Diagnosis, 2019-2024 ($)
Table 39: Europe Benign Prostatic Hyperplasia (BPH) Market, Revenue & Volume, By Treatment Procedures, 2019-2024 ($)
Table 40: APAC Benign Prostatic Hyperplasia (BPH) Market, Revenue & Volume, By Diagnosis, 2019-2024 ($)
Table 41: APAC Benign Prostatic Hyperplasia (BPH) Market, Revenue & Volume, By Treatment Procedures, 2019-2024 ($)
Table 42: Middle East & Africa Benign Prostatic Hyperplasia (BPH) Market, Revenue & Volume, By Diagnosis, 2019-2024 ($)
Table 43: Middle East & Africa Benign Prostatic Hyperplasia (BPH) Market, Revenue & Volume, By Treatment Procedures, 2019-2024 ($)
Table 44: Russia Benign Prostatic Hyperplasia (BPH) Market, Revenue & Volume, By Diagnosis, 2019-2024 ($)
Table 45: Russia Benign Prostatic Hyperplasia (BPH) Market, Revenue & Volume, By Treatment Procedures, 2019-2024 ($)
Table 46: Israel Benign Prostatic Hyperplasia (BPH) Market, Revenue & Volume, By Diagnosis, 2019-2024 ($)
Table 47: Israel Benign Prostatic Hyperplasia (BPH) Market, Revenue & Volume, By Treatment Procedures, 2019-2024 ($)
Table 48: Top Companies 2018 (US$) Benign Prostatic Hyperplasia (BPH) Market, Revenue & Volume
Table 49: Product Launch 2018-2019 Benign Prostatic Hyperplasia (BPH) Market, Revenue & Volume
Table 50: Mergers & Acquistions 2018-2019 Benign Prostatic Hyperplasia (BPH) Market, Revenue & Volume


List of Figures:

Figure 1: Overview of Benign Prostatic Hyperplasia (BPH) Market 2019-2024
Figure 2: Market Share Analysis for Benign Prostatic Hyperplasia (BPH) Market 2018 (US$)
Figure 3: Product Comparison in Benign Prostatic Hyperplasia (BPH) Market 2018-2019 (US$)
Figure 4: End User Profile for Benign Prostatic Hyperplasia (BPH) Market 2018-2019 (US$)
Figure 5: Patent Application and Grant in Benign Prostatic Hyperplasia (BPH) Market 2013-2018* (US$)
Figure 6: Top 5 Companies Financial Analysis in Benign Prostatic Hyperplasia (BPH) Market 2018-2019 (US$)
Figure 7: Market Entry Strategy in Benign Prostatic Hyperplasia (BPH) Market 2018-2019
Figure 8: Ecosystem Analysis in Benign Prostatic Hyperplasia (BPH) Market 2018
Figure 9: Average Selling Price in Benign Prostatic Hyperplasia (BPH) Market 2019-2024
Figure 10: Top Opportunites in Benign Prostatic Hyperplasia (BPH) Market 2018-2019
Figure 11: Market Life Cycle Analysis in Benign Prostatic Hyperplasia (BPH) Market
Figure 12: GlobalBy Diagnosis Benign Prostatic Hyperplasia (BPH) Market Revenue, 2019-2024 ($)
Figure 13: GlobalBy Treatment Procedures Benign Prostatic Hyperplasia (BPH) Market Revenue, 2019-2024 ($)
Figure 14: Global Benign Prostatic Hyperplasia (BPH) Market - By Geography
Figure 15: Global Benign Prostatic Hyperplasia (BPH) Market Value & Volume, By Geography, 2019-2024 ($) 
Figure 16: Global Benign Prostatic Hyperplasia (BPH) Market CAGR, By Geography, 2019-2024 (%)
Figure 17: North America Benign Prostatic Hyperplasia (BPH) Market Value & Volume, 2019-2024 ($)
Figure 18: US Benign Prostatic Hyperplasia (BPH) Market Value & Volume, 2019-2024 ($)
Figure 19: US GDP and Population, 2018-2019 ($)
Figure 20: US GDP – Composition of 2018, By Sector of Origin
Figure 21: US Export and Import Value & Volume, 2018-2019 ($)
Figure 22: Canada Benign Prostatic Hyperplasia (BPH) Market Value & Volume, 2019-2024 ($)
Figure 23: Canada GDP and Population, 2018-2019 ($)
Figure 24: Canada GDP – Composition of 2018, By Sector of Origin
Figure 25: Canada Export and Import Value & Volume, 2018-2019 ($)
Figure 26: Mexico Benign Prostatic Hyperplasia (BPH) Market Value & Volume, 2019-2024 ($)
Figure 27: Mexico GDP and Population, 2018-2019 ($)
Figure 28: Mexico GDP – Composition of 2018, By Sector of Origin
Figure 29: Mexico Export and Import Value & Volume, 2018-2019 ($)
Figure 30: South America Benign Prostatic Hyperplasia (BPH) Market Value & Volume, 2019-2024 ($)
Figure 31: Brazil Benign Prostatic Hyperplasia (BPH) Market Value & Volume, 2019-2024 ($)
Figure 32: Brazil GDP and Population, 2018-2019 ($)
Figure 33: Brazil GDP – Composition of 2018, By Sector of Origin
Figure 34: Brazil Export and Import Value & Volume, 2018-2019 ($)
Figure 35: Venezuela Benign Prostatic Hyperplasia (BPH) Market Value & Volume, 2019-2024 ($)
Figure 36: Venezuela GDP and Population, 2018-2019 ($)
Figure 37: Venezuela GDP – Composition of 2018, By Sector of Origin
Figure 38: Venezuela Export and Import Value & Volume, 2018-2019 ($)
Figure 39: Argentina Benign Prostatic Hyperplasia (BPH) Market Value & Volume, 2019-2024 ($)
Figure 40: Argentina GDP and Population, 2018-2019 ($)
Figure 41: Argentina GDP – Composition of 2018, By Sector of Origin
Figure 42: Argentina Export and Import Value & Volume, 2018-2019 ($)
Figure 43: Ecuador Benign Prostatic Hyperplasia (BPH) Market Value & Volume, 2019-2024 ($)
Figure 44: Ecuador GDP and Population, 2018-2019 ($)
Figure 45: Ecuador GDP – Composition of 2018, By Sector of Origin
Figure 46: Ecuador Export and Import Value & Volume, 2018-2019 ($)
Figure 47: Peru Benign Prostatic Hyperplasia (BPH) Market Value & Volume, 2019-2024 ($)
Figure 48: Peru GDP and Population, 2018-2019 ($)
Figure 49: Peru GDP – Composition of 2018, By Sector of Origin
Figure 50: Peru Export and Import Value & Volume, 2018-2019 ($)
Figure 51: Colombia Benign Prostatic Hyperplasia (BPH) Market Value & Volume, 2019-2024 ($)
Figure 52: Colombia GDP and Population, 2018-2019 ($)
Figure 53: Colombia GDP – Composition of 2018, By Sector of Origin
Figure 54: Colombia Export and Import Value & Volume, 2018-2019 ($)
Figure 55: Costa Rica Benign Prostatic Hyperplasia (BPH) Market Value & Volume, 2019-2024 ($)
Figure 56: Costa Rica GDP and Population, 2018-2019 ($)
Figure 57: Costa Rica GDP – Composition of 2018, By Sector of Origin
Figure 58: Costa Rica Export and Import Value & Volume, 2018-2019 ($)
Figure 59: Europe Benign Prostatic Hyperplasia (BPH) Market Value & Volume, 2019-2024 ($)
Figure 60: U.K Benign Prostatic Hyperplasia (BPH) Market Value & Volume, 2019-2024 ($)
Figure 61: U.K GDP and Population, 2018-2019 ($)
Figure 62: U.K GDP – Composition of 2018, By Sector of Origin
Figure 63: U.K Export and Import Value & Volume, 2018-2019 ($)
Figure 64: Germany Benign Prostatic Hyperplasia (BPH) Market Value & Volume, 2019-2024 ($)
Figure 65: Germany GDP and Population, 2018-2019 ($)
Figure 66: Germany GDP – Composition of 2018, By Sector of Origin
Figure 67: Germany Export and Import Value & Volume, 2018-2019 ($)
Figure 68: Italy Benign Prostatic Hyperplasia (BPH) Market Value & Volume, 2019-2024 ($)
Figure 69: Italy GDP and Population, 2018-2019 ($)
Figure 70: Italy GDP – Composition of 2018, By Sector of Origin
Figure 71: Italy Export and Import Value & Volume, 2018-2019 ($)
Figure 72: France Benign Prostatic Hyperplasia (BPH) Market Value & Volume, 2019-2024 ($)
Figure 73: France GDP and Population, 2018-2019 ($)
Figure 74: France GDP – Composition of 2018, By Sector of Origin
Figure 75: France Export and Import Value & Volume, 2018-2019 ($)
Figure 76: Netherlands Benign Prostatic Hyperplasia (BPH) Market Value & Volume, 2019-2024 ($)
Figure 77: Netherlands GDP and Population, 2018-2019 ($)
Figure 78: Netherlands GDP – Composition of 2018, By Sector of Origin
Figure 79: Netherlands Export and Import Value & Volume, 2018-2019 ($)
Figure 80: Belgium Benign Prostatic Hyperplasia (BPH) Market Value & Volume, 2019-2024 ($)
Figure 81: Belgium GDP and Population, 2018-2019 ($)
Figure 82: Belgium GDP – Composition of 2018, By Sector of Origin
Figure 83: Belgium Export and Import Value & Volume, 2018-2019 ($)
Figure 84: Spain Benign Prostatic Hyperplasia (BPH) Market Value & Volume, 2019-2024 ($)
Figure 85: Spain GDP and Population, 2018-2019 ($)
Figure 86: Spain GDP – Composition of 2018, By Sector of Origin
Figure 87: Spain Export and Import Value & Volume, 2018-2019 ($)
Figure 88: Denmark Benign Prostatic Hyperplasia (BPH) Market Value & Volume, 2019-2024 ($)
Figure 89: Denmark GDP and Population, 2018-2019 ($)
Figure 90: Denmark GDP – Composition of 2018, By Sector of Origin
Figure 91: Denmark Export and Import Value & Volume, 2018-2019 ($)
Figure 92: APAC Benign Prostatic Hyperplasia (BPH) Market Value & Volume, 2019-2024 ($)
Figure 93: China Benign Prostatic Hyperplasia (BPH) Market Value & Volume, 2019-2024
Figure 94: China GDP and Population, 2018-2019 ($)
Figure 95: China GDP – Composition of 2018, By Sector of Origin
Figure 96: China Export and Import Value & Volume, 2018-2019 ($) Benign Prostatic Hyperplasia (BPH) Market China Export and Import Value & Volume, 2018-2019 ($)
Figure 97: Australia Benign Prostatic Hyperplasia (BPH) Market Value & Volume, 2019-2024 ($)
Figure 98: Australia GDP and Population, 2018-2019 ($)
Figure 99: Australia GDP – Composition of 2018, By Sector of Origin
Figure 100: Australia Export and Import Value & Volume, 2018-2019 ($)
Figure 101: South Korea Benign Prostatic Hyperplasia (BPH) Market Value & Volume, 2019-2024 ($)
Figure 102: South Korea GDP and Population, 2018-2019 ($)
Figure 103: South Korea GDP – Composition of 2018, By Sector of Origin
Figure 104: South Korea Export and Import Value & Volume, 2018-2019 ($)
Figure 105: India Benign Prostatic Hyperplasia (BPH) Market Value & Volume, 2019-2024 ($)
Figure 106: India GDP and Population, 2018-2019 ($)
Figure 107: India GDP – Composition of 2018, By Sector of Origin
Figure 108: India Export and Import Value & Volume, 2018-2019 ($)
Figure 109: Taiwan Benign Prostatic Hyperplasia (BPH) Market Value & Volume, 2019-2024 ($)
Figure 110: Taiwan GDP and Population, 2018-2019 ($)
Figure 111: Taiwan GDP – Composition of 2018, By Sector of Origin
Figure 112: Taiwan Export and Import Value & Volume, 2018-2019 ($)
Figure 113: Malaysia Benign Prostatic Hyperplasia (BPH) Market Value & Volume, 2019-2024 ($)
Figure 114: Malaysia GDP and Population, 2018-2019 ($)
Figure 115: Malaysia GDP – Composition of 2018, By Sector of Origin
Figure 116: Malaysia Export and Import Value & Volume, 2018-2019 ($)
Figure 117: Hong Kong Benign Prostatic Hyperplasia (BPH) Market Value & Volume, 2019-2024 ($)
Figure 118: Hong Kong GDP and Population, 2018-2019 ($)
Figure 119: Hong Kong GDP – Composition of 2018, By Sector of Origin
Figure 120: Hong Kong Export and Import Value & Volume, 2018-2019 ($)
Figure 121: Middle East & Africa Benign Prostatic Hyperplasia (BPH) Market Middle East & Africa 3D Printing Market Value & Volume, 2019-2024 ($)
Figure 122: Russia Benign Prostatic Hyperplasia (BPH) Market Value & Volume, 2019-2024 ($)
Figure 123: Russia GDP and Population, 2018-2019 ($)
Figure 124: Russia GDP – Composition of 2018, By Sector of Origin
Figure 125: Russia Export and Import Value & Volume, 2018-2019 ($)
Figure 126: Israel Benign Prostatic Hyperplasia (BPH) Market Value & Volume, 2019-2024 ($)
Figure 127: Israel GDP and Population, 2018-2019 ($)
Figure 128: Israel GDP – Composition of 2018, By Sector of Origin
Figure 129: Israel Export and Import Value & Volume, 2018-2019 ($)
Figure 130: Entropy Share, By Strategies, 2018-2019* (%) Benign Prostatic Hyperplasia (BPH) Market
Figure 131: Developments, 2018-2019* Benign Prostatic Hyperplasia (BPH) Market
Figure 132: Company 1 Benign Prostatic Hyperplasia (BPH) Market Net Revenue, By Years, 2018-2019* ($)
Figure 133: Company 1 Benign Prostatic Hyperplasia (BPH) Market Net Revenue Share, By Business segments, 2018 (%)
Figure 134: Company 1 Benign Prostatic Hyperplasia (BPH) Market Net Sales Share, By Geography, 2018 (%)
Figure 135: Company 2 Benign Prostatic Hyperplasia (BPH) Market Net Revenue, By Years, 2018-2019* ($)
Figure 136: Company 2 Benign Prostatic Hyperplasia (BPH) Market Net Revenue Share, By Business segments, 2018 (%)
Figure 137: Company 2 Benign Prostatic Hyperplasia (BPH) Market Net Sales Share, By Geography, 2018 (%)
Figure 138: Company 3 Benign Prostatic Hyperplasia (BPH) Market Net Revenue, By Years, 2018-2019* ($)
Figure 139: Company 3 Benign Prostatic Hyperplasia (BPH) Market Net Revenue Share, By Business segments, 2018 (%)
Figure 140: Company 3 Benign Prostatic Hyperplasia (BPH) Market Net Sales Share, By Geography, 2018 (%)
Figure 141: Company 4 Benign Prostatic Hyperplasia (BPH) Market Net Revenue, By Years, 2018-2019* ($)
Figure 142: Company 4 Benign Prostatic Hyperplasia (BPH) Market Net Revenue Share, By Business segments, 2018 (%)
Figure 143: Company 4 Benign Prostatic Hyperplasia (BPH) Market Net Sales Share, By Geography, 2018 (%)
Figure 144: Company 5 Benign Prostatic Hyperplasia (BPH) Market Net Revenue, By Years, 2018-2019* ($)
Figure 145: Company 5 Benign Prostatic Hyperplasia (BPH) Market Net Revenue Share, By Business segments, 2018 (%)
Figure 146: Company 5 Benign Prostatic Hyperplasia (BPH) Market Net Sales Share, By Geography, 2018 (%)
Figure 147: Company 6 Benign Prostatic Hyperplasia (BPH) Market Net Revenue, By Years, 2018-2019* ($)
Figure 148: Company 6 Benign Prostatic Hyperplasia (BPH) Market Net Revenue Share, By Business segments, 2018 (%)
Figure 149: Company 6 Benign Prostatic Hyperplasia (BPH) Market Net Sales Share, By Geography, 2018 (%)
Figure 150: Company 7 Benign Prostatic Hyperplasia (BPH) Market Net Revenue, By Years, 2018-2019* ($)
Figure 151: Company 7 Benign Prostatic Hyperplasia (BPH) Market Net Revenue Share, By Business segments, 2018 (%)
Figure 152: Company 7 Benign Prostatic Hyperplasia (BPH) Market Net Sales Share, By Geography, 2018 (%)
Figure 153: Company 8 Benign Prostatic Hyperplasia (BPH) Market Net Revenue, By Years, 2018-2019* ($)
Figure 154: Company 8 Benign Prostatic Hyperplasia (BPH) Market Net Revenue Share, By Business segments, 2018 (%)
Figure 155: Company 8 Benign Prostatic Hyperplasia (BPH) Market Net Sales Share, By Geography, 2018 (%)
Figure 156: Company 9 Benign Prostatic Hyperplasia (BPH) Market Net Revenue, By Years, 2018-2019* ($)
Figure 157: Company 9 Benign Prostatic Hyperplasia (BPH) Market Net Revenue Share, By Business segments, 2018 (%)
Figure 158: Company 9 Benign Prostatic Hyperplasia (BPH) Market Net Sales Share, By Geography, 2018 (%)
Figure 159: Company 10 Benign Prostatic Hyperplasia (BPH) Market Net Revenue, By Years, 2018-2019* ($)
Figure 160: Company 10 Benign Prostatic Hyperplasia (BPH) Market Net Revenue Share, By Business segments, 2018 (%)
Figure 161: Company 10 Benign Prostatic Hyperplasia (BPH) Market Net Sales Share, By Geography, 2018 (%)
Figure 162: Company 11 Benign Prostatic Hyperplasia (BPH) Market Net Revenue, By Years, 2018-2019* ($)
Figure 163: Company 11 Benign Prostatic Hyperplasia (BPH) Market Net Revenue Share, By Business segments, 2018 (%)
Figure 164: Company 11 Benign Prostatic Hyperplasia (BPH) Market Net Sales Share, By Geography, 2018 (%)
Figure 165: Company 12 Benign Prostatic Hyperplasia (BPH) Market Net Revenue, By Years, 2018-2019* ($)
Figure 166: Company 12 Benign Prostatic Hyperplasia (BPH) Market Net Revenue Share, By Business segments, 2018 (%)
Figure 167: Company 12 Benign Prostatic Hyperplasia (BPH) Market Net Sales Share, By Geography, 2018 (%)
Figure 168: Company 13 Benign Prostatic Hyperplasia (BPH) Market Net Revenue, By Years, 2018-2019* ($)
Figure 169: Company 13 Benign Prostatic Hyperplasia (BPH) Market Net Revenue Share, By Business segments, 2018 (%)
Figure 170: Company 13 Benign Prostatic Hyperplasia (BPH) Market Net Sales Share, By Geography, 2018 (%)
Figure 171: Company 14 Benign Prostatic Hyperplasia (BPH) Market Net Revenue, By Years, 2018-2019* ($)
Figure 172: Company 14 Benign Prostatic Hyperplasia (BPH) Market Net Revenue Share, By Business segments, 2018 (%)
Figure 173: Company 14 Benign Prostatic Hyperplasia (BPH) Market Net Sales Share, By Geography, 2018 (%)
Figure 174: Company 15 Benign Prostatic Hyperplasia (BPH) Market Net Revenue, By Years, 2018-2019* ($)
Figure 175: Company 15 Benign Prostatic Hyperplasia (BPH) Market Net Revenue Share, By Business segments, 2018 (%)
Figure 176: Company 15 Benign Prostatic Hyperplasia (BPH) Market Net Sales Share, By Geography, 2018 (%)